Freeport, Bahamas (PRWEB) October 30, 2012
Matthew Feshbach, Chairman and CEO of Okyanos Heart Institute, which brings a new standard of care and a better quality of life to patients with chronic coronary artery disease (CAD) using cardiac stem cell therapy, will speak during The Atlantic’s “Big Science Summit: Science and Technology Experts on the Future of Innovation” on Tuesday, October 30, Okyanos Heart Institute announced. He will be joined by Gretchen Dezelick, Okyanos’ Director of Nursing.
Feshbach and Dezelick are integral in a case study to be presented by videoconferencing platform developer Milton Chen, during the summit’s aptly titled “Business 2.0: How Tech Will Change the Way We Work”. Okyanos was selected as an excellent example of technology’s positive impact on the near future of medicine. Part of Atlantic’s specialized AtlanticLIVE events, the summit brings thought leaders and engaged audiences together for challenging conversations about forward-thinking critical issues.
Chen’s presentation will showcase Okyanos’ use of digital videoconference abilities to bring together physicians and patients worldwide with specialists at Okyanos, while concurrently connecting Okyanos with referring physicians to discuss patient health with total security. It provides a platform for Okyanos’ ongoing collaboration of physicians, researchers and scientists from around the world communicate, share information and expertise through the most updated videoconferencing available.
Feshbach and Dezelick will participate from offices in the U.S. and The Bahamas, respectively. They are joined by Andrew McAfee, principle investigator at Center for Digital Business at the Sloan School of MIT, and Steve Clemons, Washington editor-at-large for The Atlantic and the editor of AtlanticLIVE, who will moderate the panel.
“Grand Bahama Island is proving itself to becoming a leading provider of healthcare services to the international community,” explained Feshbach. “Okyanos Health Institute looks forward to its ever-evolving role in improving lives of countless patients suffering from chronic coronary artery disease. Our success lies in joining the best minds with the utmost in technology to provide the greatest outcomes in life quality for our patients.”
Matthew Feshbach added: “Given patient privacy regulations it is crucial we use top-level security to protect all patient information. VSee finally means we can discuss patient matters in private with confidence.”